This story was originally published on Manufacturing Dive. To receive daily news and insights, subscribe to our free daily ...

Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to ...

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported ...

Regeneron Pharmaceuticals, Inc. REGN reported first-quarter 2025 adjusted earnings per share (EPS) of $8.22, which missed the ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull ...

On Tuesday, Fujifilm Diosynth announced a 10-year agreement worth more than $3 billion to make medicines for the New York drugmaker Regeneron in the Triangle. Regeneron is the facility’s third major ...

Regeneron boosts antibody profits with higher Dupixent sales and expands biologics production via FUJIFILM Diosynth ...

As pharma giants line up one after another to tout their investment plans in the U.S., Regeneron is adopting a different tack ...

The EC has granted conditional marketing approval to Regeneron Pharmaceuticals’ bispecific antibody Lynozyfic for treating ...

Agreement secures additional U.S. manufacturing capacity to help ensure patient access to medicineHOLLY SPRINGS, N.C., April 23, 2025 -- ...

Regeneron Pharmaceuticals has announced a new manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies to enhance its production capacity for biologic medicines at Fujifilm's ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) experienced a 7% price increase over the past week, coinciding with the European Commission's regulatory approval of Lynozyfic for relapsed and refractory ...